A Functional Outcomes Study With Atomoxetine-Hydrochloride and Placebo in Adults With Attention-Deficit/Hyperactivity Disorder

NCT00190931 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

400

Enrollment

INDUSTRY

Sponsor class

Conditions

Attention Deficit Disorder With Hyperactivity

Interventions

DRUG: Atomoxetine Hydrochloride
DRUG: placebo

Sponsor

Eli Lilly and Company